Given that immune checkpoint inhibitors (i.e., anti–PD-1 Abs) have been successful in cancer treatment and have revolutionized the cancer research field (11), an increasing number of patients with cancer have undergone immune checkpoint therapy (27). This evidence concerns the gene PDCD1 and cancer.